Compound beauty filler containing decellularized placenta extract and preparation method of compound beauty filler

Abstract

The invention belongs to the technical field of biomedical materials, and particularly relates to a compound beauty filler containing a decellularized placenta extract and a preparation method of the compound beauty filler. The composite beauty filler containing the acellular placenta extract, disclosed by the invention, is prepared from the following raw materials in parts by weight: 0.1 to 0.5 part of the acellular placenta extract, 0.05 to 0.1 part of calcium alginate, 0.01 to 0.05 part of mucus peptide and 1 to 3 parts of a hydrogel matrix material. The obtained beauty filler not only has a better filling effect, but also has higher safety, durability and anti-inflammatory and antioxidant activity.

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedical materials, and in particular, relates to a composite cosmetic filler containing acellular placenta extract and a preparation method thereof. Background Art

[0002] Placenta, also known as "Zi Chehe", is a commonly used Chinese medicine. It is a special tissue of mammals that provides nutrients to the fetus during pregnancy and allows the embryo to grow. It is excreted from the body during childbirth. Because of its special barrier function and endocrine function, it has been valued by people since ancient times. Human placental extracts (human placenta l extracts, HPE) refer to a series of small molecule active substances extracted from human placenta, including: collagen, growth factors, amino acids, active peptides, etc. Studies have found that HPE has multiple functions, including regulation of the autonomic nervous system and endocrine system, enhancing immune function, anti-inflammatory effects, scavenging free radicals, promoting wound healing, liver detoxification, fatigue recovery, and increasing appetite. HPE can promote wound healing by regulating trypsin activity. It is widely used in the beauty field due to its significant antioxidant activity. It is also used to culture adult stem cells for translational research in regenerative medicine because it contains a variety of cytokines and chemokines that are essential for the maintenance and differentiation of stem cells. It can also activate the expression of a series of genes related to skin function to improve skin condition. It can also improve LPS-induced lung inflammation in mice by activating anti-inflammatory factors.

[0003] As a specific structural protein, the characteristics and advantages of natural collagen have been widely recognized and have become one of the important raw materials for biomedical materials. Human placenta is very rich in collagen and contains multiple types of collagen, so it is a very valuable raw material for preparing natural medical collagen. Various types of natural medical collagen products prepared using human placenta as raw materials do not carry infectious diseases on the one hand, and on the other hand overcome the risks of possible bacterial contamination or potential zoonotic diseases when using xenobiotic animal tissues or organs as raw materials to prepare collagen. At the same time, it also overcomes the rejection reaction of xenobiotic use. Therefore, human placental extracts, especially placental collagen, are safer when used as cosmetic fillers. Summary of the invention

[0004] The purpose of the present invention is to provide a composite cosmetic filler containing acellular placenta extract and a preparation method thereof. The composite cosmetic filler is a biomedical material and belongs to a different type from cosmetics. The technical scheme of the present invention enables the obtained cosmetic filler to have higher safety, biocompatibility and anti-inflammatory and antioxidant activity.

[0005] To this end, the present invention provides the following technical solutions.

[0006] One aspect of the present invention provides a composite cosmetic filler containing acellular placenta extract. The raw materials include, by weight: 0.1-0.5 parts of acellular placenta extract, 0.05-0.1 parts of calcium alginate, 0.01-0.05 parts of mucus peptide, and 1-3 parts of hydrogel matrix material.

[0007] In a preferred embodiment of the present invention, the raw materials include, by weight: 0.1-0.5 parts of acellular placenta extract, 0.05-0.1 parts of calcium alginate, 0.01-0.05 parts of spirulina mucus peptide, and 1-3 parts of hydrogel matrix material.

[0008] In a preferred embodiment of the present invention, the raw materials include, by weight: 0.1-0.5 parts of acellular placenta extract, 0.05-0.1 parts of calcium alginate, 0.01-0.05 parts of snail mucus peptide, and 1-3 parts of hydrogel matrix material.

[0009] In a preferred embodiment of the present invention, the method for preparing the hydrogel matrix material comprises:

[0010] Dissolving carboxymethylcellulose calcium and hyaluronic acid in water in a mass ratio of 1 to 2:5 to 10:100 to obtain a carboxymethylcellulose calcium / hyaluronic acid mixed solution;

[0011] Dissolving a bifunctional coupling compound and silver nitrate in a 60-80% by volume organic alcohol solution at a mass ratio of 1:0.01-0.05:100 and subjecting the solution to ultrasonic treatment to obtain a silver ion-modified bifunctional coupling compound mixed solution;

[0012] N-vinyl functional monomer and initiator are added to the obtained carboxymethyl cellulose calcium / hyaluronic acid mixed solution to carry out polymerization reaction. After the reaction, a silver ion-modified bifunctional coupling compound mixed solution is added to the obtained product in a volume ratio of 1:0.1-0.3 and continuously stirred at 40-60°C for 2-4 hours, then allowed to stand for 8-12 hours, and finally filtered, and the obtained gel is washed and dried to obtain a hydrogel matrix material.

[0013] In a preferred embodiment of the present invention, the bifunctional coupling compound is selected from any one of disuccinimidyl suberate, disuccinimidyl adipate, and disuccinimidyl succinate, or a mixture of two or more thereof.

[0014] In a preferred embodiment of the present invention, the organic alcohol is selected from any one of ethanol, propanol and propylene glycol.

[0015] In a preferred embodiment of the present invention, the ultrasonic conditions are: power 600-800W, time 30-60min.

[0016] In a preferred embodiment of the present invention, the functional monomer is selected from any one of N-vinyl caprolactam, N-vinylimidazole and vinyl pyrrolidone.

[0017] In a preferred embodiment of the present invention, the added amount of the functional monomer is 1 to 3 times the mass of hyaluronic acid.

[0018] In a preferred embodiment of the present invention, the initiator is selected from any one of ammonium persulfate, potassium persulfate and sodium persulfate.

[0019] In a preferred embodiment of the present invention, the added amount of the initiator is 0.3-0.5% of the mass of the functional monomer.

[0020] In a preferred embodiment of the present invention, the composite cosmetic filler further comprises physiological saline, and the content of the physiological saline is 80 to 120 parts by weight.

[0021] By means of the above technical solution, the present invention has at least the following advantages:

[0022] 1. The composite cosmetic filler containing acellular placenta extract of the present invention not only has excellent filling and repairing effect, but also can maintain the filling effect for a long time, and is a cosmetic repair material with great potential and application prospects. The preparation method of the present invention is simple and suitable for industrial production.

[0023] 2. The present invention uses decellularized placenta extract and mucus peptide as main active substances, supplemented with calcium alginate and hydrogel matrix material, and uses hydrogel matrix material as carrier. Under the crosslinking effect of calcium alginate, decellularized placenta extract and mucus peptide are crosslinked on the hydrogel matrix material to form a stable polymer with a three-dimensional network structure. The main component of decellularized placenta extract is human placenta collagen, which has good biocompatibility and is not easy to produce rejection reaction. Mucus peptide is a small molecule peptide with anti-inflammatory and antioxidant activity. Therefore, the obtained filler not only has a good filling effect, but also has high safety, durability and anti-inflammatory and antioxidant activity.

[0024] The above description is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention and implement it according to the contents of the specification, the preferred embodiments of the present invention are described in detail as follows. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 This is a physical picture of the decellularized placenta extract;

[0026] Figure 2 It is a comparison chart of the in vitro degradation of the composite cosmetic fillers of Examples 1-3 and Comparative Examples 1-4. DETAILED DESCRIPTION

[0027] In order to make the technical means, creative features, objectives and effects of the present invention easy to understand, the technical solutions in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0028] Unless otherwise specified, the human placental collagen, the main active substance in the decellularized placenta extract used in the following examples, is prepared by referring to patent CN103525890A, specifically:

[0029] Select fresh complete human placenta obtained through disease screening and normal delivery. The placenta tissue is fully cleaned and cut into small pieces, centrifuged to remove the supernatant after low-temperature homogenization, and the precipitate is washed with deionized water and then centrifuged again, and the washing and centrifugation are repeated 4 times until the supernatant is transparent; the precipitate is soaked with 0.5 mol / L tris-hydrochloric acid (Tris-HCl) buffer with a pH of 7.2, containing 10mmol / L sodium ethylenediaminetetraacetic acid (Na2EDTA) and 1.0mol / L NaCl, and slowly stirred for 4h; after stirring, centrifuge, the obtained precipitate is washed once with Tris-HCl buffer and centrifuged, and finally the precipitate is centrifuged. The obtained precipitate is soaked in a digestive solution, which is a 0.5 mol / L acetic acid solution with a pH of 2.8 and a pepsin (activity 500U / mg) concentration of 5g / L, and the mass of the digestive solution is 5 times the weight of the precipitate, and the precipitate is continuously and slowly stirred under low temperature conditions. After enzyme digestion for 12h, the enzyme is inactivated, and then centrifuged to obtain a supernatant. The obtained supernatant was filtered through a 0.22 μm microfiltration membrane to collect the filtrate. The obtained filtrate was concentrated to obtain the acellular placenta extract. Figure 1 shown.

[0030] Unless otherwise specified, the Spirulina mucus peptide used in the following examples is prepared as follows:

[0031] Spirulina powder and water were mixed in a mass ratio of 1:10 to prepare algae liquid, and then the algae liquid was broken by high-pressure homogenization to obtain a broken wall Spirulina liquid. The obtained broken wall Spirulina liquid was placed in an ultrasonic reactor and ultrasonically extracted at 800W for 30 minutes to obtain an extraction solution. The obtained extract was centrifuged twice to obtain a supernatant. A composite enzyme preparation of papain (activity 500U / mg) and alkaline protease (activity 500U / mg) in a mass ratio of 1:1 was added to the obtained supernatant and enzymolysis was performed for 12 hours. After the enzymolysis was completed, the enzyme was inactivated and centrifuged to obtain a supernatant. The obtained supernatant was placed in a nanofiltration device for filtration, the molecular weight of the nanofiltration membrane was 1000Da, the operating pressure was 1.5MPa, the membrane surface flow rate was controlled at 3m / s, and the filtrate was collected. The obtained filtrate was concentrated and freeze-dried to obtain Spirulina mucus peptide.

[0032] Unless otherwise specified, the snail mucus peptide used in the following examples is prepared by referring to patent CN103525890A, specifically:

[0033] Select snails with larger size and more than four and a half months of age, place them in a mucus extractor to extract, and obtain purified mucus. Take out the snail meat, remove the internal organs, clean them, and crush them into a homogenate. The obtained homogenate and mucus are mixed evenly in a volume ratio of 1:1 to obtain a mixed homogenate; the obtained mixed homogenate is placed in an ultrasonic reactor and ultrasonically extracted at 800W for 30 minutes to obtain an extraction solution. The obtained extraction solution is centrifuged twice to obtain a supernatant. Neutral protease (activity 600U / mg) is added to the obtained supernatant and enzymolysis is performed for 12 hours. After the enzymolysis is completed, the enzyme is inactivated, and then centrifuged to obtain a supernatant. The obtained supernatant is placed in a nanofiltration device for filtration, the molecular weight of the nanofiltration membrane is 1000Da, the operating pressure is 1.5MPa, the membrane surface flow rate is controlled at 3m / s, and the filtrate is collected. The obtained filtrate is concentrated and freeze-dried to obtain snail mucus peptide.

[0034] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods.

[0035] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0036] Embodiment 1:

[0037] Preparation of hydrogel matrix material: Carboxymethylcellulose calcium and hyaluronic acid (molecular weight 200,000 Da, CAS No.: 9004-61-9, Guangdong Wengjiang Chemical Reagent Co., Ltd.) were dissolved in water at a mass ratio of 1.5:7.5:100 to obtain a carboxymethylcellulose calcium / hyaluronic acid mixed solution. Disuccinimidyl suberate and silver nitrate were dissolved in a 70% ethanol solution by volume at a mass ratio of 1:0.03:100 and ultrasonically treated at 700 W for 45 min to obtain a silver ion-modified disuccinimidyl suberate mixed solution. N-vinyl caprolactam (the amount added is 2 times the mass of hyaluronic acid) and ammonium persulfate (the amount added is 0.4% of the mass of N-vinyl caprolactam) are added to the obtained carboxymethyl cellulose calcium / hyaluronic acid mixed solution for polymerization reaction for 4 hours. After the reaction, a silver ion-modified disuccinimidyl suberate mixed solution is added to the obtained product in a volume ratio of 1:0.2 and continuously stirred for 3 hours at 50°C. The mixture is then allowed to stand for 10 hours and finally filtered. The obtained gel is washed and dried to obtain a hydrogel matrix material.

[0038] Preparation of composite cosmetic filler: According to weight proportions, 0.3 parts of decellularized placenta extract, 0.075 parts of calcium alginate, 0.03 parts of mucin, 2 parts of hydrogel matrix material and 100 parts of physiological saline are mixed evenly, and the mixture is sterilized and packaged.

[0039] Embodiment 2:

[0040] Preparation of hydrogel matrix material: Carboxymethylcellulose calcium and hyaluronic acid (molecular weight 200,000 Da, CAS No.: 9004-61-9, Guangdong Wengjiang Chemical Reagent Co., Ltd.) were dissolved in water at a mass ratio of 1:5:100 to obtain a carboxymethylcellulose calcium / hyaluronic acid mixed solution. Disuccinimidyl adipate and silver nitrate were dissolved in a 60% volume fraction ethanol solution at a mass ratio of 1:0.05:100 and ultrasonically treated at 600 W for 60 min to obtain a silver ion-modified disuccinimidyl adipate mixed solution. N-vinylimidazole (the amount added is 1 times the mass of hyaluronic acid) and potassium persulfate (the amount added is 0.3% of the mass of N-vinylimidazole) are added to the obtained carboxymethylcellulose calcium / hyaluronic acid mixed solution to carry out polymerization reaction for 3 hours. After the reaction is completed, a silver ion-modified disuccinimidyl adipate mixed solution is added to the obtained product in a volume ratio of 1:0.3 and continuously stirred for 2 hours at 60°C. Then, the mixture is allowed to stand for 8 hours and finally filtered. The obtained gel is washed and dried to obtain a hydrogel matrix material.

[0041] Preparation of composite cosmetic filler: According to weight proportions, 0.1 part of decellularized placenta extract, 0.05 part of calcium alginate, 0.05 part of mucin, 1 part of hydrogel matrix material and 80 parts of physiological saline are mixed evenly, and the mixture is sterilized and packaged.

[0042] Embodiment 3:

[0043] Preparation of hydrogel matrix material: Carboxymethylcellulose calcium and hyaluronic acid (molecular weight 200,000 Da, CAS No.: 9004-61-9, Guangdong Wengjiang Chemical Reagent Co., Ltd.) were dissolved in water at a mass ratio of 2:10:100 to obtain a carboxymethylcellulose calcium / hyaluronic acid mixed solution. Disuccinimidyl succinate and silver nitrate were dissolved in an 80% ethanol solution by volume at a mass ratio of 1:0.01:100 and ultrasonically treated at 800 W for 30 min to obtain a silver ion-modified disuccinimidyl succinate mixed solution. Vinyl pyrrolidone (the amount added is 3 times the mass of hyaluronic acid) and sodium persulfate (the amount added is 0.5% of the mass of vinyl pyrrolidone) are added to the obtained carboxymethyl cellulose calcium / hyaluronic acid mixed solution for polymerization reaction for 5 hours. After the reaction, a silver ion-modified disuccinimidyl succinate mixed solution is added to the obtained product in a volume ratio of 1:0.1 and continuously stirred at 40°C for 4 hours, then allowed to stand for 12 hours, and finally filtered, the obtained gel is washed and dried to obtain a hydrogel matrix material.

[0044] Preparation of composite cosmetic filler: According to weight proportions, 0.5 parts of decellularized placenta extract, 0.1 parts of calcium alginate, 0.01 parts of mucin, 3 parts of hydrogel matrix material and 120 parts of physiological saline are mixed evenly, and the mixture is sterilized and packaged.

[0045] Comparative Example 1: Disuccinimidyl suberate mixed solution without silver ion modification

[0046] Preparation of hydrogel matrix material: Carboxymethylcellulose calcium and hyaluronic acid (molecular weight 200,000 Da, CAS No.: 9004-61-9, Guangdong Wengjiang Chemical Reagent Co., Ltd.) were dissolved in water in a mass ratio of 1.5:7.5:100 to obtain a carboxymethylcellulose calcium / hyaluronic acid mixed solution. N-vinyl caprolactam (the amount added was 2 times the mass of hyaluronic acid) and ammonium persulfate (the amount added was 0.4% of the mass of N-vinyl caprolactam) were added to the obtained carboxymethylcellulose calcium / hyaluronic acid mixed solution to carry out polymerization reaction for 4 hours, and after the reaction was completed, the mixture was allowed to stand for 10 hours, and finally filtered, and the obtained gel was washed and dried to obtain a hydrogel matrix material.

[0047] Preparation of composite cosmetic filler: According to weight proportions, 0.3 parts of decellularized placenta extract, 0.075 parts of calcium alginate, 0.03 parts of mucin, 2 parts of hydrogel matrix material and 100 parts of physiological saline are mixed evenly, and the mixture is sterilized and packaged.

[0048] Comparative Example 2: 2 parts of hydrogel matrix material were not added

[0049] Preparation of composite cosmetic filler: According to weight proportions, 0.3 parts of acellular placenta extract, 0.075 parts of calcium alginate, 0.03 parts of mucin and 100 parts of physiological saline are mixed evenly, and the mixture is sterilized and packaged.

[0050] Comparative Example 3: No addition of 0.03 parts of mucus peptide

[0051] Preparation of hydrogel matrix material: Carboxymethylcellulose calcium and hyaluronic acid (molecular weight 200,000 Da, CAS No.: 9004-61-9, Guangdong Wengjiang Chemical Reagent Co., Ltd.) were dissolved in water at a mass ratio of 1.5:7.5:100 to obtain a carboxymethylcellulose calcium / hyaluronic acid mixed solution. Disuccinimidyl suberate and silver nitrate were dissolved in a 70% ethanol solution by volume at a mass ratio of 1:0.03:100 and ultrasonically treated at 700 W for 45 min to obtain a silver ion-modified disuccinimidyl suberate mixed solution. N-vinyl caprolactam (the amount added is 2 times the mass of hyaluronic acid) and ammonium persulfate (the amount added is 0.4% of the mass of N-vinyl caprolactam) are added to the obtained carboxymethyl cellulose calcium / hyaluronic acid mixed solution for polymerization reaction for 4 hours. After the reaction, a silver ion-modified disuccinimidyl suberate mixed solution is added to the obtained product in a volume ratio of 1:0.2 and continuously stirred for 3 hours at 50°C. The mixture is then allowed to stand for 10 hours and finally filtered. The obtained gel is washed and dried to obtain a hydrogel matrix material.

[0052] Preparation of composite cosmetic filler: According to weight proportions, 0.3 parts of decellularized placenta extract, 0.075 parts of calcium alginate, 2 parts of hydrogel matrix material and 100 parts of physiological saline are mixed evenly, and the mixture is sterilized and packaged.

[0053] Comparative Example 4: 2 parts of hydrogel matrix material and 0.03 parts of mucus peptide were not added

[0054] Preparation of composite cosmetic filler: According to weight proportions, 0.3 parts of acellular placenta extract, 0.075 parts of calcium alginate and 100 parts of physiological saline are uniformly mixed, and the mixture is sterilized and packaged.

[0055] Test 1: In vitro degradation test

[0056] With reference to "GB16886 Biological Evaluation of Medical Devices", the composite cosmetic fillers prepared in Examples 1 to 3 and Comparative Examples 1 to 4 were placed in sterile PBS buffer (pH 7.2) and placed at 37°C to observe degradation. The mass ratio of the samples was measured at 1 month, 3 months, 6 months, 9 months, 12 months, 15 months, and 18 months. During the measurement, the supernatant was discarded by centrifugation at 5000g for 15 minutes, and the precipitate was washed with purified water 3 times. The final precipitate was freeze-dried and its mass ratio was calculated. The results are shown in Table 1 and Figure 2 .

[0057] Mass ratio (%) = mass of sample after degradation / mass of sample before degradation × 100%

[0058] Table 1 Comparison of in vitro degradation

[0059]

[0060]

[0061] From Table 1 and Figure 2 It can be seen from the results that the filler products of Examples 1-3 of the present invention degrade significantly slower than the products of Comparative Examples 1-4. The filler products of Examples 1-3 of the present invention are basically completely degraded after 18 months, while the products of Comparative Examples 1-4 begin to degrade completely after 12 months and are basically completely degraded after 15 months. The above results show that the filler products of Examples 1-3 of the present invention can achieve the goal of faster onset and longer duration.

[0062] Test 2: Skin irritation test

[0063] 21 SPF Wistar rats, 6 weeks old, weighing 200±20g, half male and half female, were selected. They were housed in separate cages and maintained at room temperature, relative humidity (50±5)%, 12h light and dark alternation, free access to food and water. The 21 rats were randomly divided into 7 groups, 3 rats in each group, and skin irritation test was performed.

[0064] According to the multi-point microinjection method, the deep subcutaneous tissue injection sites on both sides of the rat back were injected at a specified interval. The specific injection method was: each group of rats was fasted for 12 hours before the operation, and the drinking was forbidden for 4 hours. 7% chloral hydrate (0.03mL / kg body weight) was used for intraperitoneal injection anesthesia. After anesthesia, the skin of the local injection site on the back of the rat was prepared, and the local area was wiped with 75% medical alcohol for routine disinfection according to the aseptic principle. The products of Example 1 and Comparative Examples 1-4 were injected into each group of rats respectively. The injection situation of each rat was: the distance between the injection site needle points was 1cm, the injection dose of each site was 10μL, and a total of 0.2ml was injected. After the injection, moderate massage was given, and the situation within 48h after the injection was observed. The results are shown in Table 2.

[0065] Table 2 Skin reactions of mice in each group

[0066]

[0067] It can be seen from the results in Table 2 that the products of Examples 1-3 and Comparative Examples 1-4 of the present invention have no obvious irritation to rats.

[0068] Trial 3: Clinical wrinkle improvement

[0069] 15 healthy volunteers were selected as test subjects, aged between 35 and 45 years old, including 5 males and 10 females. All volunteers were randomly divided into 5 groups, with 3 volunteers in each group, and the effects of the composite cosmetic filler composition of Example 1 and Comparative Examples 1-4 on human skin wrinkles under experimental conditions were investigated. The cosmetic filler composition of Example 1 and Comparative Examples 1-4 was injected into the periocular skin of each group of volunteers, respectively, and the specific injection method was: the injection volume was 50 μL each time, the injection point interval was 1 cm, and the total injection dose was 2 mL. The wrinkle improvement at the injection site before injection, 2 days after injection, and 7 days after injection was counted, and the results were averaged. The wrinkle score was 1 to 10 points, 10 points for the highest wrinkle level, 1 point for the lowest wrinkle level, and no wrinkles. The score was scored by a professional cosmetic physician. During the experiment, the volunteers in each group maintained basically the same diet and lifestyle. The results are shown in Table 3.

[0070] Table 3 Wrinkle improvement of volunteers in each group

[0071]

[0072]

[0073] As can be seen from Table 3, after the injection of the composite cosmetic filler composition of Example 1 and Comparative Examples 1-4, the wrinkles of the volunteers in each group were significantly reduced; however, compared with the products of Comparative Examples 1-4, the wrinkle improvement of the volunteers after injection of the filler of Example 1 of the present invention was significantly better. The above results show that the composite cosmetic filler composition prepared by Example 1 of the present invention has the effect of reducing wrinkles after injection, and also has the effect of softening the skin, rejuvenating the skin, and maintaining a youthful state.

[0074] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technician familiar with this profession can make some changes or modifications to equivalent embodiments of equivalent changes by using the methods and technical contents disclosed above without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the technical solution of the present invention.

Claims

1. A composite cosmetic filler containing acellular placenta extract, characterized in that: In terms of weight, the raw materials include: 0.1-0.5 parts of decellularized placenta extract, 0.05-0.1 parts of calcium alginate, 0.01-0.05 parts of mucus peptide and 1-3 parts of hydrogel matrix material.

2. The composite cosmetic filler containing acellular placenta extract according to claim 1, characterized in that: In terms of weight, the raw materials include: 0.1-0.5 parts of decellularized placenta extract, 0.05-0.1 parts of calcium alginate, 0.01-0.05 parts of spirulina mucus peptide and 1-3 parts of hydrogel matrix material.

3. The composite cosmetic filler containing acellular placenta extract according to claim 1, characterized in that: In terms of weight, the raw materials include: 0.1-0.5 parts of decellularized placenta extract, 0.05-0.1 parts of calcium alginate, 0.01-0.05 parts of snail mucus peptide and 1-3 parts of hydrogel matrix material.

4. The composite cosmetic filler containing acellular placenta extract according to any one of claims 1 to 3, characterized in that: The preparation method of the hydrogel matrix material comprises: Dissolving carboxymethylcellulose calcium and hyaluronic acid in water in a mass ratio of 1 to 2:5 to 10:100 to obtain a carboxymethylcellulose calcium / hyaluronic acid mixed solution; Dissolving a bifunctional coupling compound and silver nitrate in a 60-80% by volume organic alcohol solution at a mass ratio of 1:0.01-0.05:100 and subjecting the solution to ultrasonic treatment to obtain a silver ion-modified bifunctional coupling compound mixed solution; N-vinyl functional monomer and initiator are added to the obtained carboxymethyl cellulose calcium / hyaluronic acid mixed solution to carry out polymerization reaction. After the reaction, a silver ion-modified bifunctional coupling compound mixed solution is added to the obtained product in a volume ratio of 1:0.1-0.3 and continuously stirred at 40-60°C for 2-4 hours, then allowed to stand for 8-12 hours, and finally filtered, and the obtained gel is washed and dried to obtain a hydrogel matrix material.

5. The composite cosmetic filler containing acellular placenta extract according to claim 4, characterized in that: The bifunctional coupling compound is selected from any one of disuccinimidyl suberate, disuccinimidyl adipate, and disuccinimidyl succinate, or a mixture of two or more thereof.

6. The composite cosmetic filler containing acellular placenta extract according to claim 4, characterized in that: The organic alcohol is selected from any one of ethanol, propanol and propylene glycol.

7. The composite cosmetic filler containing acellular placenta extract according to claim 4, characterized in that: The ultrasonic conditions are: power 600-800W, time 30-60min.

8. The composite cosmetic filler containing acellular placenta extract according to claim 4, characterized in that: The functional monomer is selected from any one of N-vinyl caprolactam, N-vinylimidazole and vinyl pyrrolidone; The added amount of the functional monomer is 1 to 3 times the mass of hyaluronic acid.

9. The composite cosmetic filler containing acellular placenta extract according to claim 4, characterized in that: The initiator is selected from any one of ammonium persulfate, potassium persulfate, and sodium persulfate; The added amount of the initiator is 0.3-0.5% of the mass of the functional monomer.

10. The composite cosmetic filler containing acellular placenta extract according to any one of claims 1 to 3, characterized in that: The composite cosmetic filler also contains physiological saline, and the content of the physiological saline is 80 to 120 parts by weight.

Images